Stockreport

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada p [Read more]